|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Minnesota Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MinnesotaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Vyriad
| Vyriad 221 1st Ave SW, Suite 102 Rochester, MN 55902 | |
| | Phone: | (888) 666-6898 | Year Established: | 2016 | Main Contact: | Stephen J. Russell MD PhD, Co-Founder, CEO & President | | Other Contacts: | Shruthi Naik Ph.D., Co-Founder and VP, Comparative Oncology Janey Russell, VP, Operations Jim Hannon, CFO
| | Company Description | Vyriad is a clinical-stage biotechnology company developing novel oncolytic virus therapies for the treatment of cancers that have significant unmet need. Vyriad’s oncolytic immunovirotherapy products are based on the company’s engineered Oncolytic Vesicular Stomatitis Virus (VSV) and Oncolytic Measles Virus platforms that enable selective destruction of cancer cells without harming normal tissues. Vyriad’s product development pipeline encompasses multiple clinical- and preclinical-stage programs that target a broad range of cancer indications as well as programs that pair the company’s oncolytic viruses with other cancer immunotherapy modalities, traditional cancer therapy, and newer targeted therapies. In addition, Vyriad is developing novel diagnostic/ theranostic tests for more accurate prediction of immunovirotherapy response. Clinical trials using the company’s oncolytic viruses are under way at Mayo Clinic and the University of Arkansas. | |
|
|
|
|
|